Sarepta Therapeutics Earnings Preview: Recent Insider Trading and Hedge Fund Activity
Sarepta Therapeutics (SRPT) is gearing up to reveal its financial performance for the last quarter on November 3rd after the market closes, according to Finnhub. Market analysts predict revenue of approximately $342,827,518 and a per-share earnings figure of -$0.85. Interested parties can refer to Quiver Quantitative’s page dedicated to SRPT stock for a comprehensive look at insider trading, hedge fund activities, congressional trading, and more.
The hedge fund landscape for Sarepta Therapeutics saw a mixed bag of activity in the previous quarter, with 204 institutional investors increasing their stake in the company while 244 institutions reduced their positions. Notable moves include Capital International Investors shedding 8,562,435 shares, equivalent to a 94.5% reduction in their holdings, valued at an estimated $146,417,638. On the other hand, D. E. Shaw & Co., Inc. significantly augmented its position by adding 4,474,232 shares, marking a colossal 101548.6% increase, with an estimated worth of $76,509,367. These shifts and others can be closely monitored through Quiver Quantitative’s institutional holdings dashboard.
In terms of analyst sentiment towards SRPT, recent reports have seen a mix of opinions, with 8 firms issuing buy ratings for the stock and 4 advising to sell. Noteworthy recent ratings include BMO Capital’s “Outperform” rating on 09/22/2025 and Guggenheim’s “Buy” rating on 09/15/2025. On the flip side, B of A Securities gave a “Underperform” rating on 08/21/2025, indicating a bearish outlook. To track the latest analyst ratings and price targets for Sarepta Therapeutics, individuals can refer to Quiver Quantitative’s SRPT forecast page.
Multiple analysts have recently weighed in on price targets for SRPT, with a median target pegged at $21.0 among 26 analysts over the last half-year. These targets vary widely, with recent price points including Piper Sandler’s $16.0, BMO Capital’s $50.0, and Guggenheim’s $22.0. Such insights offer a glimpse into the diverse perspectives analysts hold regarding the future trajectory of Sarepta Therapeutics’ stock price.
As a note of caution, readers should bear in mind that the information provided in this article is not intended as financial advice. Any inaccuracies or discrepancies may arise due to errors in ticker-mapping and other anomalies. It is always advisable to conduct thorough research and due diligence before making investment decisions.